For years, Ligand Pharmaceuticals urged the Securities and Exchange Commission to pursue one of the drug company’s critics. It got nowhere.
In late 2018, it finally got its wish: The SEC filed civil fraud charges against Gregory Lemelson, an ordained Greek Orthodox priest who also runs a tiny hedge fund in Massachusetts. The agency alleges that he falsely disparaged Ligand to profit from his short position in the stock.
